Drug Profile
Polyomavirus-specific T cells - AlloVir
Alternative Names: BKV-specific T cell therapy - AlloVir; BKV-specific T cells - AlloVir; HLA-matched BKV-specific T cells - AlloVir; HLA-matched Viralym-B cells; Human leukocyte antigen (HLA)-matched BK virus-specific T lymphocytes - AlloVir; Polyomavirus-specific T cell therapy - AlloVir; Viralym-BLatest Information Update: 19 Jul 2019
Price :
$50
*
At a glance
- Originator ViraCyte
- Class T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Human polyomavirus infections